Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
33.3%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (50.0%)
Phase 41 (50.0%)

Trials by Status

recruiting125%
terminated250%
completed125%

Recent Activity

1 active trials
Showing 4 of 4
recruiting

The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research

NCT03158090
completed

Stress, Diurnal Cortisol, and Breast Cancer Survival

NCT00226967
terminatedphase_4

Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation

NCT04140409
terminatedphase_2

Sandostatin for Patients With Androgen Independent Prostate Cancer

NCT00510224

Clinical Trials (4)

Showing 4 of 4 trials
NCT03158090

The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research

Recruiting
NCT00226967

Stress, Diurnal Cortisol, and Breast Cancer Survival

Completed
NCT04140409Phase 4

Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation

Terminated
NCT00510224Phase 2

Sandostatin for Patients With Androgen Independent Prostate Cancer

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4